Aurinia Pharmaceuticals Inc. (AUPH) P/E Ratio History
UndervaluedTrading at 7.9x vs 5Y avg 42.2x · 43th percentile · Below historical baseline · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, Aurinia Pharmaceuticals Inc. (AUPH) trades at a price-to-earnings ratio of 7.9x, with a stock price of $16.40 and trailing twelve-month earnings per share of $2.35.
The current P/E is 81% below its 5-year average of 42.2x. Over the past five years, AUPH's P/E has ranged from a low of 6.9x to a high of 204.6x, placing the current valuation at the 43th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, AUPH trades at a 67% discount to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 167.0x.
Relative to the broader market, AUPH trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our AUPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
AUPH Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
AUPH P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $6B | 48.7 | - | +2886%Best | |
| $2B | 22.4 | - | +419% | |
| $12B | 137.7 | - | -33% | |
| $100B | 13.5Lowest | - | +124% | |
| $34B | 25.8 | - | -21% | |
| $33B | 105.8 | - | +207% | |
| $44B | 34.2 | 0.84Best | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
AUPH Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $16.97 | $2.29 | 7.4x | -82% |
| FY2026 Q1 | - | $14.82 | $2.16 | 6.9x | -84% |
| FY2025 Q4 | Dec 31 2025 | $15.95 | $2.07 | 7.7x | -82% |
| FY2025 Q3 | - | $11.05 | $0.55 | 20.1x | -52% |
| FY2025 Q2 | Jun 30 2025 | $8.47 | $0.42 | 20.2x | -52% |
| FY2025 Q1 | Mar 31 2025 | $8.04 | $0.28 | 28.9x | -32% |
| FY2024 Q4 | - | $8.98 | $0.04 | 204.6x | +384% |
Average P/E for displayed period: 42.2x
AUPH Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AUPH — Frequently Asked Questions
Quick answers to the most common questions about buying AUPH stock.
What is AUPH's P/E ratio?
Aurinia Pharmaceuticals Inc. (AUPH) trailing twelve-month P/E ratio is 7.9x, based on TTM diluted EPS of $2.35. The 5-year average P/E is 42.2x and the historical range spans 6.9x to 204.6x.
Is AUPH stock overvalued or undervalued?
AUPH trades at 7.9x P/E, below its 5-year average of 42.2x. At the 43th percentile of its historical range (6.9x–204.6x), the stock is priced at a discount to its own history.
Is AUPH stock expensive?
No, AUPH is not expensive on a historical basis. The current P/E of 7.9x is below the 5-year average of 42.2x and sits at the 43th percentile of its valuation range.
What is AUPH's historical P/E range?
Over the past 5 years, AUPH's P/E ratio has ranged from 6.9x to 204.6x, with a median of 20.1x and an average of 42.2x. The current P/E of 7.9x places the stock at the 43th percentile of this range. Full historical data spans 2024–2026.
How does AUPH's P/E compare to the S&P 500?
AUPH trades at 7.9x P/E versus the S&P 500 median of 25.3x. The 69% discount to the market suggests lower growth expectations or perceived higher risk.
How does AUPH's valuation compare to Healthcare peers?
Aurinia Pharmaceuticals Inc. P/E of 7.9x compares to the Healthcare sector median of 23.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is AUPH's PEG ratio?
AUPH PEG ratio is N/A, based on a P/E of 7.9x and EPS growth of 5167.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is AUPH's earnings yield?
AUPH earnings yield is 12.62%, the inverse of its 7.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.